The APEH Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This model features a targeted disruption of the APEH gene, which encodes acylaminoacyl-peptide hydrolase, an enzyme responsible for removing N-acetylated amino acids from peptides. The polyclonal format provides a heterogeneous population of cells with diverse editing outcomes, reflecting a range of loss-of-function alleles suitable for studying gene function in a cancer-relevant background without the clonal selection bias inherent in monoclonal lines.
The A-549 cell line, originally isolated from a 58-year-old male patient with lung adenocarcinoma, is a widely employed model in respiratory and cancer biology. Its epithelial origin and well-characterized growth properties make it particularly useful for investigating tumor cell behavior, drug responses, and metabolic adaptations. A-549 cells retain key features of lung adenocarcinoma, including KRAS mutation and p53 status, providing a clinically relevant context for knockout studies.
APEH functions as a serine peptidase that hydrolyzes N-acetylated peptides, playing a critical role in the final steps of protein degradation and N-terminal protein processing. Within the broader protein degradation pathway, APEH acts downstream of proteasomal and lysosomal proteolysis, cooperating with aminoacylases, N-acetyltransferases, and other peptidases. Although upstream regulators remain largely uncharacterized, the enzyme??s activity generates deacetylated proteins and peptides that feed into subsequent metabolic and signaling processes. Disruption of APEH therefore perturbs normal peptide turnover, leading to accumulation of N-acetylated amino acids and peptides, which may influence cellular metabolism and protein homeostasis.
In A-549 lung adenocarcinoma cells, APEH knockout provides a powerful tool to dissect the enzyme??s contribution to tumor metabolism and protein quality control. Given the high metabolic demands of cancer cells, loss of APEH-mediated deacetylation could alter the pool of free amino acids and acetylated intermediates, potentially affecting anabolic pathways and stress responses. This model enables systematic analysis of how impaired N-terminal processing impacts lung cancer cell proliferation, survival, and metabolic reprogramming, thereby advancing our understanding of APEH as a candidate vulnerability in adenocarcinoma.
Researchers can employ this knockout model in a variety of downstream assays, including Western blotting and RT-qPCR for confirming APEH disruption, enzyme activity assays with N-acetylated substrates, and LC-MS-based profiling of acetylated peptides. Functional studies may incorporate cellular metabolism assessments via Seahorse analysis, proliferation and apoptosis assays by flow cytometry, and transcriptomic characterization through RNA-seq. These applications support investigations into N-terminal protein processing in lung cancer, protein degradation pathway dynamics, and target validation for therapeutic intervention. For additional information or to request a quote, please contact Ascent Research.
